Solvotrin Therapeutics

Solvotrin Therapeutics Limited is a privately held pharmaceutical company focused on cardiovascular applications. Solvotrin’s business model is based on the development of new drugs that combine its unique patented prodrug platform with well established compounds in large markets. Its approach of chemically creating new chemical entities from existing compounds for synergistic benefits creates efficacy and safety advantages with significantly reduced development timeline and development risk. Solvotrin’s lead compound, ST0702 is a nicotinic acid prodrug, with significant efficacy and tolerability advantages over similar products for 54 dyslipidaemia. ST0701 is a bioactivated form of aspirin, which addresses the well documented gastrointestinal toxicity of aspirin. ST0703 is a ’nitro-aspirin‘ prodrug with dual antiplatelet effects and disease modifying potential. The company has a strong intellectual property underpin with patent protection at the highest, New Molecule level. Solvotrin’s strategy is to take its compounds to the end of Phase I and to partner the development and commercialisation phases with large pharmaceutical companies.

show less